What's happening
This bill allows insurance plans to treat interchangeable biologics and biosimilars like generics in drug coverage and formulary tiering.
Why it matters
Expanding Tiering Options. By explicitly allowing insurance plans to treat interchangeable biologics and biosimilars like generics in formulary tiering, the bill could encourage insurers to promote lower-cost alternatives to expensive brand-name biologic drugs, potentially lowering out-of-pocket costs for patients.
Drug Switching and Stability. The bill clarifies that insurance utilization review agents can require patients to try not just generics, but also interchangeable biologics or biosimilars, even if a patient is stable on their current brand-name medication. This could impact continuity of care and may raise concerns for patients and providers about forced medication switches.
Market Incentives for Biosimilars. Treating biosimilars and interchangeable biologics like generics in insurance coverage could accelerate their adoption in the marketplace, driving competition and possibly leading to further reductions in drug prices over time.
Potential Impact on Access and Choice. While intended to save costs, these changes could also limit patient and provider choice by making it easier for insurers to move brand-name drugs to less favorable tiers when a biosimilar or interchangeable product becomes available. This could result in higher costs for patients who need or prefer the original biologic.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Health insurers and utilization review agents
The bill would let them require patients stable on a prescribed drug to try an interchangeable biological product or biosimilar before covering the equivalent brand-name drug.
Patients stable on brand-name prescription drugs
They could face a requirement to try a biological alternative before receiving coverage, even when stable on their current treatment.
Insurers with tiered drug formularies
The bill would let them move a drug to a higher cost-sharing tier when they simultaneously add a biosimilar for that drug to the formulary.
Prescribing health care professionals
Their patients’ stable treatment regimens could become subject to requirements to try interchangeable biological products or biosimilars before brand-name coverage.
Headline styles
Expand Drug Substitution Options
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to insurance
- Referred to rules
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Cover Biologics and Biosimilars
In Assembly Committee · Insurance · Sponsor John T. McDonald III
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
7768
2023-2024 Regular Sessions
IN SENATE
November 27, 2023
Introduced by Sen. HINCHEY -- read twice and ordered printed, and when printed to be committed to the Committee on Rules
AN ACT to amend the insurance law, in relation to prescription drug formulary coverage for interchangeable biologics and biosimilars
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Paragraph 4 of subsection (c-1) of section 4903 of the insurance law, as added by chapter 512 of the laws of 2016, is amended to read as follows:
(4) The insured is stable on a prescription drug or drugs selected by their health care professional for the medical condition under consideration, provided that this shall not prevent a utilization review agent from requiring an insured to try an AB-rated generic equivalent, an interchangeable biological product , or biosimilar prior to providing coverage for the equivalent brand name prescription drug or drugs; or
§ 2. Subparagraph (A) of paragraph 3 of subsection (c) of section 3242 of the insurance law, as added by chapter 99 of the laws of 2022, is amended to read as follows:
(A) An insurer with a formulary that includes two or more tiers of benefits providing for different deductibles, copayments or coinsurance applicable to prescription drugs in each tier may move a prescription drug to a tier with a larger deductible, copayment or coinsurance if an AB-rated generic equivalent [or], an interchangeable biological product, or biosimilar for such prescription drug is added to the formulary at the same time.
§ 3. Subparagraph (A) of paragraph 3 of subsection (c) of section 4329 of the insurance law, as added by chapter 99 of the laws of 2022, is amended to read as follows:
(A) A corporation with a formulary that includes two or more tiers of benefits providing for different deductibles, copayments or coinsurance applicable to prescription drugs in each tier may move a prescription
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD11861-01-3
drug to a tier with a larger deductible, copayment or coinsurance if an AB-rated generic equivalent [or], an interchangeable biological product, or biosimilar for such prescription drug is added to the formulary at the same time.
§ 4. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the insurance law, in relation to prescription drug formulary coverage for interchangeable biologics and biosimilars
Purpose
To reduce prescription drug costs in New York by allowing biosimilar medicines to be substituted for the original biologics.
Summary of provisions
Section one amends section 4903 of the Insurance law to add both inter- changeable biologics and biosimilars to New York's step therapy proto- col, allowing utilization review agents to require an insured to try an interchangeable biologic or biosimilar medication before covering the name brand drug.
Section two amends section 3242 of the Insurance law to allow insurance companies to move a reference drug to a tier with a larger deductible, copayment, or coinsurance if a biosimilar version of that drug exists and is added to the formulary at the same time.
Section three amends section 4329 of the Insurance law to allow non-pro- fit insurance companies to move a reference drug to a tier with a larger deductible, copayment, or coinsurance if a biosimilar version of that drug exists and is added to the formulary at the same time.
Justification
Biological medications or 'biologics' are on the cutting edge of medical technology and are used to treat complicated conditions and diseases including cancer, rheumatoid arthritis, diabetes and multiple sclerosis. These drugs are often life-changing and life-saving, but they are also delicate and complicated to produce. Biologics are made using living organisms that produce the proteins required to make the medication.This makes these medications incredibly cost prohibitive for companies to develop and test,resulting in high costs to patients and insurance companies.
However, alternative versions of biologics called 'biosimilars' have been developed.Biosimilars are an FDA-approved drug that is similar to an existing biologic medication (or reference drug) and produces the same outcome. Biosimilars are produced by manufacturers who did not develop the original biologic. Because these manufacturers did not have to finance the extensive costs associated with biologic development, they can sell the medication at a lower cost. In addition, biosimilars undergo an abbreviated FDA approval process because the reference biologic has demonstrated the medication's effectiveness. This shorter proceeding further reduces development costs for biosimilar manufactur- ers and contributes to lower biosimilar prices.
This bill would amend New York State's insurance law to allow insurance providers to require their insureds to try a biosimilar medication instead of the reference drug and place a biosimilar in a less expensive tier of prescription medication. This would generate cost savings for both the patient and the insurance company, making access to medication more affordable.
Legislative history
New Bill.
Fiscal implications
To be determined.
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.